Which Peptide Is Tirzepatide? | FormBlends

Trust Signals

Key Takeaways

• Tirzepatide is a 39-amino-acid synthetic peptide engineered to activate both GIP and GLP-1 receptors, making it the first approved dual incretin receptor agonist.
• Its backbone is derived from the native GIP sequence, modified at multiple positions, with a C20 fatty diacid attached at lysine-26 to enable once-weekly dosing via albumin binding.
• In SURMOUNT-1 (n=2539), the 15 mg dose produced approximately 20.9% mean body weight reduction over 72 weeks, the largest weight loss seen in any approved pharmacological agent at the time of publication.
• An alpha-aminoisobutyric acid (aib) substitution at position 2 blocks DPP-4 cleavage, the primary reason native GIP and GLP-1 have half-lives of only minutes while tirzepatide achieves roughly 5 days.
• The FDA removed tirzepatide from its drug shortage list in early 2025, materially changing the legal status of compounded tirzepatide preparations.

Which Peptide Is Tirzepatide? (Direct Answer)

What Class of Peptide Is Tirzepatide?

Tirzepatide belongs to the incretin mimetic class of therapeutic peptides. Incretins are gut-derived hormones released in response to food intake that amplify insulin secretion in a glucose-dependent manner. The two principal human incretins are GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Tirzepatide is classified as a dual GIP/GLP-1 receptor agonist, or twincretin, because it activates both receptor types with clinically meaningful potency.

Within peptide chemistry, tirzepatide is a fatty-acid-conjugated, non-native peptide analogue. It is not a peptide fragment, not a growth factor peptide, and not a cytokine. It is synthesized through solid-phase peptide synthesis and is not derived from animal tissue extraction.

What Is the Exact Structure of the Tirzepatide Peptide?

The tirzepatide amino acid sequence is 39 residues. According to the published INN monograph and characterization data from Eli Lilly, key structural features include:

• Position 2: Alpha-aminoisobutyric acid (aib) replaces the native alanine found in GIP. This single change eliminates DPP-4 protease recognition and is the primary mechanism preventing rapid plasma degradation.
• Position 13: An arginine substitution contributes to GLP-1 receptor binding that is absent in native GIP.
• Position 26: Lysine with a C20 fatty diacid conjugated via a gamma-glutamic acid and two mini-PEG linker units. This modification drives non-covalent albumin binding, which is the mechanism for extending the half-life from minutes to approximately 5 days.
• C-terminus: Amidated, which improves metabolic stability compared to a free acid terminus.

The molecular weight of tirzepatide is approximately 4,813 daltons. Its molecular formula is C225H348N48O68. These figures appear in the FDA Mounjaro prescribing information published at the time of the May 2022 approval.

How Does Tirzepatide Work at the Receptor Level?

Tirzepatide binds to and activates the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), both of which are G-protein-coupled receptors (GPCRs) that signal primarily through the Gs/cAMP pathway. Receptor activation triggers:

• Pancreatic beta cells: Glucose-dependent insulin secretion, meaning tirzepatide amplifies insulin release only when blood glucose is elevated. This is why hypoglycemia is uncommon as monotherapy.
• Pancreatic alpha cells: Suppression of glucagon secretion via GLP-1R activation, reducing hepatic glucose output.
• Hypothalamus and brainstem: GLP-1R agonism reduces appetite signaling and increases satiety. GIP receptor expression in the central nervous system is also documented, and its contribution to appetite regulation is an area of active research (mechanism established, exact CNS contribution in humans not fully quantified).
• Gastric motility: Slowed gastric emptying via GLP-1R, which reduces postprandial glucose excursions and contributes to satiety.
• Adipose tissue: GIPR activation in adipocytes may improve lipid handling. This is supported by preclinical data and is considered a contributing but not fully characterized mechanism in humans.

Importantly, GLP-1R potency of tirzepatide in in vitro assays is lower than that of semaglutide, yet clinical outcomes are comparable or superior. This discrepancy suggests the GIP component is additive or synergistic rather than irrelevant, though the exact weighting is still being studied.

Evidence Ledger: What Does the Clinical Data Actually Show?

What Most Pages Get Wrong About Tirzepatide as a Peptide

Most content on tirzepatide describes it as a "GLP-1 drug" and moves on. This misclassification has real consequences for understanding its pharmacology.

Misconception 1: Tirzepatide is a GLP-1 analogue. It is not. Its backbone is closer to GIP. It was engineered to gain GLP-1 receptor activity, not the reverse. This distinction matters because GIPR agonism has different tissue distribution effects, particularly in adipose tissue and potentially the CNS, than GLP-1R agonism.

Misconception 2: Greater weight loss means stronger GLP-1 effect. In vitro, tirzepatide shows lower GLP-1R agonist potency than semaglutide. The superior clinical weight loss is therefore not explained by GLP-1 activity alone. The dual mechanism likely drives the added efficacy, but the exact contribution of each receptor in humans is not definitively isolated in any single trial.

Misconception 3: Compounded tirzepatide is identical to branded tirzepatide. The peptide sequence can be replicated synthetically, but the exact fatty acid linker chemistry, the enantiomeric purity, and the excipient formulation (pH, preservative type, tonicity agent) influence safety and activity. A certificate of analysis (COA) showing peptide purity by HPLC does not confirm correct linker attachment or stereochemical integrity. Compounding pharmacies may use different synthesis routes, and independent verification of structural equivalence to the branded product is not standard practice.

Misconception 4: Tirzepatide is shelf-stable at room temperature indefinitely. The peptide backbone, particularly the amide bonds, undergoes hydrolysis. The fatty acid conjugate can oxidize. Refrigeration slows both pathways. The FDA-approved label permits a maximum of 21 days at up to 30 degrees Celsius for branded product; beyond this, activity loss is expected, though specific degradation kinetics for tirzepatide at elevated temperatures are proprietary and not publicly published in granular form.

Why Does Tirzepatide Last a Week? The Chemistry Behind the Rule

Native GLP-1 has a plasma half-life of 1 to 2 minutes. Native GIP survives slightly longer (roughly 5 to 7 minutes) because it has partial DPP-4 resistance, but both are rapidly inactivated. Tirzepatide achieves a half-life of approximately 5 days through two independent chemical strategies working together:

Strategy 1: DPP-4 blockade via aib at position 2. DPP-4 (dipeptidyl peptidase-4) cleaves the second amino acid from the N-terminus of peptides when that position contains alanine or proline. Native GIP has alanine at position 2. Tirzepatide replaces this with alpha-aminoisobutyric acid (aib), which has a methyl group on both the alpha carbon. This extra methyl group creates steric hindrance that prevents DPP-4 from accessing and cleaving the peptide bond. No cleavage means the peptide remains intact after subcutaneous injection and survives in circulation.

Strategy 2: Albumin binding via fatty diacid conjugation. The C20 fatty diacid at lysine-26 is connected through a spacer (gamma-glutamic acid and mini-PEG units). This fatty chain associates non-covalently with hydrophobic pockets on human serum albumin (HSA). Albumin has a natural half-life of approximately 19 days. When tirzepatide is bound to albumin, it is temporarily protected from renal filtration (albumin at roughly 69,000 daltons cannot pass the glomerulus) and from proteolytic enzymes. The peptide cycles between free and albumin-bound states, extending its effective circulation time to roughly 5 days. This is the same fundamental approach used by semaglutide, though the specific linker architecture differs.

Understanding this chemistry matters practically: anything that competes for albumin binding sites (such as high-dose salicylates or certain antibiotics) could theoretically alter tirzepatide pharmacokinetics by displacing it from albumin. This is acknowledged as a theoretical interaction in pharmacology literature but has not been characterized as a clinically significant drug interaction in the current prescribing information.

Honest Head-to-Head: Tirzepatide vs. Semaglutide vs. Liraglutide

Honest note: Cross-trial weight loss comparisons are imperfect. SURMOUNT-1 and STEP-1 had different populations, run-in procedures, and baseline BMIs. The numbers above represent published means, not a controlled equivalence test.

Operational and Label Literacy: How to Read a Tirzepatide Product

Whether evaluating a branded autoinjector or a compounded vial, the following checks matter:

For branded product (Mounjaro/Zepbound):

• Confirm the NDC number matches the Eli Lilly product. Counterfeit GLP-1 pens have been reported to the FDA and DEA.
• Inspect the solution. It should be clear and colorless to slightly yellow. Cloudiness, particulates, or discoloration mean do not use.
• Check the lot number and expiration date. Refrigerated shelf life is approximately 24 months from manufacture; always verify the printed expiration on the carton.

For compounded tirzepatide (where legally permitted):

• Request the certificate of analysis (COA) from the compounding pharmacy. It should show HPLC purity (look for greater than 98% target peak as a reasonable threshold, though standards vary) and confirm the correct molecular weight by mass spectrometry.
• Ask specifically whether the COA confirms fatty acid conjugation. A COA that only shows peptide backbone purity does not confirm the C20 fatty diacid linker is correctly attached. Without this, the compound will have a half-life of minutes rather than days.
• Reconstitution: if supplied lyophilized, use bacteriostatic water (not sterile water) for multi-dose vials. Use the volume specified by the compounding pharmacy. Mixing math: if a vial contains 5 mg of tirzepatide and you add 1 mL of bacteriostatic water, the concentration is 5 mg/mL, meaning a 0.5 mg dose requires 0.1 mL drawn in an insulin syringe. Confirm units with the prescribing provider.
• Reconstituted vials should be refrigerated and are typically stable for a limited period (often cited as up to 28 days when refrigerated and protected from light, though compounding pharmacy-specific stability data should govern this).
• Signs of degradation: any color change, cloudiness, or visible aggregation. A degraded peptide may also simply be inactive with no visible change, which is why temperature excursion logs matter.

Regulatory Status and Compounding Reality

Tirzepatide (Mounjaro) received FDA approval for type 2 diabetes on May 13, 2022. Tirzepatide (Zepbound) received FDA approval for chronic weight management on November 8, 2023. Both approvals are for subcutaneous injection, manufactured by Eli Lilly.

From late 2022 through early 2025, tirzepatide was on the FDA's drug shortage list. During that period, 503A and 503B compounding pharmacies could prepare tirzepatide under conditions set by FDA guidance. In early 2025, the FDA declared the shortage resolved and issued guidance that compounding pharmacies could no longer routinely compound tirzepatide. As of this writing, the regulatory landscape for compounded tirzepatide is significantly restricted, and individual pharmacies and prescribers should consult current FDA guidance and applicable state pharmacy board rules before any compounding activity.

FAQ

Which peptide is tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at both GIP and GLP-1 receptors. It is not a naturally occurring peptide but a designed analogue with a fatty diacid moiety attached at lysine-26 for extended half-life.

Is tirzepatide a GLP-1 or GIP peptide?

Tirzepatide is both. It is engineered to activate GLP-1 receptors and GIP receptors simultaneously. Its backbone is most closely based on the native GIP sequence, but it has been modified to gain meaningful GLP-1 receptor affinity, making it a dual incretin receptor agonist.

How long is the tirzepatide peptide chain?

Tirzepatide contains 39 amino acids. Its sequence diverges from native GIP at multiple positions to optimize dual receptor activity and resistance to DPP-4 cleavage.

What makes tirzepatide different from semaglutide structurally?

Semaglutide is a 34-amino-acid GLP-1 analogue with a single fatty acid chain attached at lysine-26 via a linker. Tirzepatide is a 39-amino-acid dual GIP/GLP-1 agonist with a C20 fatty diacid attached at lysine-26. The dual receptor targeting and GIP component are the key structural and pharmacological differences.

How does tirzepatide's half-life compare to other peptides?

Tirzepatide has a terminal half-life of approximately 5 days, supporting once-weekly dosing. Semaglutide has a similar half-life of about 7 days. Native GLP-1 and GIP have half-lives of minutes due to DPP-4 cleavage. The fatty diacid modification enables albumin binding that dramatically extends circulation time.

Is tirzepatide FDA approved?

Yes. The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023.

What clinical trial data supports tirzepatide for weight loss?

SURMOUNT-1 (Jastreboff et al., NEJM 2022, n=2539) showed tirzepatide 15 mg produced approximately 20.9% mean body weight reduction over 72 weeks versus 3.1% for placebo. This is the primary human RCT supporting weight loss efficacy.

What are the most common side effects of tirzepatide?

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These are dose-dependent and typically most pronounced during dose escalation. Serious but uncommon risks include pancreatitis and a theoretical (rodent-based, not confirmed in humans) thyroid C-cell concern.

Can tirzepatide be used as a compounded peptide?

During the FDA drug shortage period ending in early 2025, compounding pharmacies could legally prepare tirzepatide under certain conditions. Following shortage resolution, the FDA significantly restricted compounded tirzepatide. The regulatory status should be verified at the time of prescribing.

How is tirzepatide degraded in the body?

Tirzepatide is metabolized through proteolytic degradation of the peptide backbone and fatty acid beta-oxidation. The aib substitution at position 2 protects against DPP-4 cleavage, which would otherwise inactivate it within minutes as with native GIP and GLP-1.

Does tirzepatide need refrigeration?

Yes. Branded tirzepatide should be stored refrigerated at 36 to 46 degrees Fahrenheit. It may be kept at room temperature up to 86 degrees Fahrenheit for up to 21 days. Exposure to heat or freezing degrades the peptide structure and reduces potency.

Is tirzepatide the same as semaglutide or Ozempic?

No. They are different peptides with different sequences and different receptor targets. Semaglutide targets GLP-1 receptors only. Tirzepatide targets both GLP-1 and GIP receptors. Available trial data shows tirzepatide produces greater average weight loss, though no large direct head-to-head RCT has been published as of this writing.

Related peptide guides

• Peptide therapy guide hub
• Peptide dosage and reconstitution calculator
• What Peptide Is Ozempic? | FormBlends
• What Peptide Is Tirzepatide? | FormBlends
• What Peptides Are in Tirzepatide? | FormBlends
• Tirzepatide Peptide: Evidence, Mechanism & Research Reality | FormBlends
• Survodutide Peptide: Dual GLP-1/Glucagon Receptor Agonist Evidence | FormBlends